Prof. Howard L. Kaufman Director for Rush University Cancer Center, Rush University Medical Center and Associate dean for Rush medical college, Chicago, Illinois, USA. The major research interests of Prof. Kaufman include Tumor Immunology and Immunotherapy, Melanoma, cytokines, tumor vaccines, immune monitoring.

Prof. John Maher
practises as a consultant immunologist at both King's College Hospital and Barnet and Chase Farm Hospitals and is senior lecturer in immunology at King's College Hospital. His primary research interest is adoptive T-cell immunotherapy of cancer using chimeric antigen receptor (CAR) engineered T-cells. He trained at Memorial Sloan Kettering Cancer Center before establishing the "CAR Mechanics Group" at King's College London. In addition, he has recently initiated a second research group focussed on adoptive immunotherapy using gamma delta T-cells.

Prof. Guillermo D. Mazzolini
Director of Gene Therapy laboratory at Austral University. Holds a position as Independent Investigator of the National Council for Scientific and Technological Research (CONICET) and associate director of the Department of Academic Development at Hospital Universitario Austral where he practices as hepatologist. The major research interests of Prof. Mazzolini includes immuno-gene therapy for gastrointestinal carcinomas with cytokines, dendritic cells as cancer vaccines, and study of tumor-induced immunossupressive mechanisms.

Biotherapy, Immunomodulators, Cancer immunotherapy, Cancer vaccines, Cryoimmunotherapy, Monoclonal antibody therapy, Activation immunotherapy, Passive immunotherapy, Cell based immunotherapy, Translational immunotherapy, Chemoimmunotherapy, Tumour-infiltrating lymphocytes, Cytotoxic T Lymphocytes, Radioimmunotherapy, Anti-microbial immunotherapy, Restorative immunotherapy, Immunocompromised patients, Suppressive immunotherapy, Genetically engineered T cells, Transplantation immunotherapy, Helminthic Therapy, Immunotherapy biomarkers, Allergy vaccines, Immunotherapeutic approaches, Drug interactions, Drug delivery systems, Drug combinations, Immunotherapeutic agents, Immune targets.

Tweets by @JImmunotherAppl